Suven Life Sciences Reports Declining Financial Metrics Amid Challenging Landscape in August 2025

Suven Life Sciences, a small-cap player in the healthcare services industry, recently announced its financial results for the quarter ending June 2025. The report, released on August 13, 2025, highlights a challenging financial landscape for the company.
The evaluation changes indicate a shift in the company's score, which has moved to -10 from -11 over the past three months. This adjustment reflects ongoing difficulties in key financial metrics. The Profit Before Tax (PBT) for the quarter stands at Rs -52.12 crore, marking a notable decline compared to the average PBT of the previous four quarters. Similarly, the Profit After Tax (PAT) has also shown a downward trend, recorded at Rs -51.52 crore, which is significantly lower than the average PAT from earlier periods.

Additionally, the Debtors Turnover Ratio has reached its lowest point at 4.97 times, indicating a slowdown in the company's ability to settle its debts. Operating cash flow has also been reported at Rs -47.39 crore, the lowest in three years, suggesting a decline in cash revenues from business operations. Furthermore, the Earnings per Share (EPS) has hit a low of Rs -2.36, reflecting reduced profitability for shareholders.

For more insights on Suven Life Sciences and its financial performance, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.